Literature DB >> 7621881

Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.

H J Gruss1, D Ulrich, S Braddy, R J Armitage, S K Dower.   

Abstract

The CD30 ligand (CD30L) and CD40L are members of the tumor necrosis factor (TNF) protein superfamily, CD30L and CD40L are mainly expressed as membrane-bound proteins by activated T cells. CD30L and CD40L are costimulatory for T cell proliferation and activation. Further, CD40L is a critical signal for T cell-dependent activation of B cells. Primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells, the neoplastic component of Hodgkin's disease (HD), express high levels of the counterreceptors CD30 and CD40. We have found that both the recombinant CD30L and CD40L enhanced interleukin (IL)-6, TNF and lymphotoxin (LT)-alpha release from cultured H-RS cells. In addition, CD40L, but not CD30L, induced IL-8 secretion. CD30L and CD40L seem to share some redundant biological activities involved in the deregulated secretion of cytokines known to play a central role in the clinical presentation and pathology of HD. Further, CD30L enhanced surface expression of intercellular adhesion molecule-1 (ICAM-1/CD54) on cultured H-RS cells, which is frequently overexpressed on primary H-RS cells. CD30L- and CD40L-enhanced CD54 surface expression is followed by elevated shedding of CD54, as shown by detection of elevated 82-kDa soluble (s) CD54 levels in culture supernatants after stimulation with both ligands. CD30L and CD40L share common pleiotropic biological activities on CD30+/CD40+ H-RS cells and are elements of the cytokine and cell contact-dependent activation network typical for HD, a tumor of cytokine producing cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621881     DOI: 10.1002/eji.1830250742

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

2.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells.

Authors:  A Cerutti; A Schaffer; S Shah; H Zan; H C Liou; R G Goodwin; P Casali
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

3.  CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2.

Authors:  E N Tsitsikov; D A Wright; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors:  Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal:  Mol Ther       Date:  2015-01-13       Impact factor: 11.454

5.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

6.  CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

Authors:  H J Gruss; A Pinto; A Gloghini; E Wehnes; B Wright; N Boiani; D Aldinucci; V Gattei; V Zagonel; C A Smith; M E Kadin; C von Schilling; R G Goodwin; F Herrmann; A Carbone
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

7.  CD40 is a prognostic marker in primary cutaneous malignant melanoma.

Authors:  J J van den Oord; A Maes; M Stas; J Nuyts; S Battocchio; A Kasran; M Garmyn; I De Wever; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

8.  Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

Authors:  K Warzocha; J Bienvenu; P Ribeiro; I Moullet; C Dumontet; E M Neidhardt-Berard; B Coiffier; G Salles
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.